# New clinical trials in Panama: 29 since Nov 2024

Updated October 22, 2026.

29 clinical studies with a site in Panama were first posted on ClinicalTrials.gov from November 13, 2024 to October 22, 2026; 21 have an industry sponsor and 19 are recruiting or about to. The newest, NCT07889492, was posted on October 22, 2026: A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo (Edesa Biotech Inc.).

## The full list

New clinical trials with a site in Panama: 29 rows for $5, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/country/panama

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 29
- Industry sponsored: 21
- Recruiting or not yet: 19
- Latest posted: October 22, 2026

## Newest trials

The newest 29 of 29, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2026 | NCT07889492 | A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo | Edesa Biotech Inc. | Phase 2 | Recruiting | Non-Segmental Vitiligo (NSV) | 80 | Canada, Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889492) |
| September 9, 2026 | NCT07809113 | PCV21 Acceptance in Adults ≥50 Years and Caregivers in Panama | Endpoints Site Network | Observational | Not yet recruiting | Pneumococcal Immunization | 600 | Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809113) |
| September 9, 2026 | NCT07808697 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to \<12 Years of Age | ModernaTX, Inc. | Phase 2 | Recruiting | SARS-CoV-2 | 300 | Argentina, Dominican Republic, Mexico, Panama, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808697) |
| August 4, 2026 | NCT07745621 | Vivifi Device Safety Evaluation for the Treatment of Benign Prostatic Hyperplasia | Vivifi Medical | Not applicable | Not yet recruiting | Benign Prostatic Hyperplasia | 20 | Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07745621) |
| July 21, 2026 | NCT07717320 | Suicidal Risk in Adults in Panama: Validation of a Clinical Intervention Protocol | Fundación Judío Panameña (JUPA) | Not applicable | Not yet recruiting | Suicide Risk | 300 | Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07717320) |
| July 13, 2026 | NCT07698353 | A Clinical Feasibility Study of the Aquea Intracanalicular Glaucoma Micro-coil Stent | Aquea Health, Inc. | Not applicable | Active not recruiting | Glaucoma, Open-Angle, Cataract Senile | 29 | Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07698353) |
| May 1, 2026 | NCT07561502 | Transurethral Periprostatectomy Treatment of Cancerous Prostate Tissue | Francis Medical Inc. | Not applicable | Completed | Prostate Cancer | 32 | Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07561502) |
| April 21, 2026 | NCT07542184 | Nanochon Chondrograft First in Human (FIH) Early Feasibility Study (EFS) - Panama | Nanochon, Inc. | Not applicable | Recruiting | Knee Cartilage Lesions | 5 | Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07542184) |
| March 16, 2026 | NCT07473557 | Clinical Outcomes of the Use of a Femtosecond Laser on an Implanted Intraocular Lens | Perfect Lens, LLC | Not applicable | Completed | Refractive Error Correction | 12 | Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07473557) |
| January 28, 2026 | NCT07371468 | A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD) | GlaxoSmithKline | Phase 1 | Recruiting | Systemic Lupus Erythematosus | 44 | Argentina, Brazil, France, Italy, Japan, Panama, Poland, Spain, Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07371468) |
| December 16, 2025 | NCT07286331 | A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based... | GlaxoSmithKline | Phase 3 | Recruiting | Neoplasms, Endometrial | 600 | Argentina, Australia, Brazil, Canada, Israel, Japan, Panama, South Korea... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07286331) |
| December 4, 2025 | NCT07265336 | Excess Base Comparison Between Pregnant Subjects With Severe Preeclampsia vs. Normotensive Pregnant Women | Saint Thomas Hospital, Panama | Not applicable | Completed | Preeclampsia, Severe Preeclampsia | 100 | Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07265336) |
| December 3, 2025 | NCT07261956 | Lung Ultrasound for the Detection of Volume Overload in Patients With Severe Preeclampsia | Saint Thomas Hospital, Panama | Not applicable | Recruiting | Pulmonary Edema - Acute, Preeclampsia | 202 | Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07261956) |
| November 25, 2025 | NCT07249996 | Respiratory Infections in Young Children | Eduardo Lopez -Medina | Observational | Recruiting | Respiratory Tract Infections (RTI), Lower Respiratory Tract Infection (LRTI), Viral Infections, Cohort Study | 1,088 | Colombia, Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07249996) |
| November 21, 2025 | NCT07243405 | Neurostimulation for Sleep Disordered Breathing (SDB) | Lunair Medical | Not applicable | Recruiting | Sleep Disordered Breathing (SDB), Sleep Apnea | 45 | Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07243405) |
| August 29, 2025 | NCT07147192 | Feasibility Study of an Accommodating IOL Design | Alcon Research | Not applicable | Terminated | Aphakia | 17 | Costa Rica, Dominican Republic, El Salvador, Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07147192) |
| August 5, 2025 | NCT07103148 | A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population | Sanofi | Phase 3 | Active not recruiting | Yellow Fever Immunization | 2,440 | Honduras, Mexico, Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07103148) |
| July 11, 2025 | NCT07060222 | Intestinal Preparation in Colonoscopy: Lactulose vs Sodium Phosphate. | Hospital Civil de Guadalajara | Phase 4 | Recruiting | Bowel Preparation for Colonoscopy | 300 | Mexico, Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07060222) |
| June 25, 2025 | NCT07036510 | Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery | EyeD Pharma | Phase 1/2 | Recruiting | Glaucoma, Ocular Hypertension | 42 | Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07036510) |
| May 30, 2025 | NCT06997159 | A Clinical Trial to Investigate Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Oral Miltefosine as Active... | Drugs for Neglected Diseases | Phase 2 | Not yet recruiting | Localized Cutaneous Leishmaniasis | 250 | Brazil, Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06997159) |
| May 27, 2025 | NCT06991270 | OMNI 3.1 Surgical System in Subjects With Primary Open-Angle Glaucoma | Sight Sciences, Inc. | Not applicable | Active not recruiting | Primary Open Angle Glaucoma | 25 | Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06991270) |
| May 11, 2025 | NCT06965582 | A Pilot Study Of The ALPFA Benign Prostatic Hyperplasia (BPH) Pulsed Field Ablation (PFA) System | ALPFA Medical | Not applicable | Enrolling by invitation | Benign Prostatic Hyperplasia | 100 | Czechia, Italy, Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06965582) |
| April 29, 2025 | NCT06948773 | A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX) | Sight Sciences, Inc. | Not applicable | Active not recruiting | Primary Open Angle Glaucoma, Cataract | 25 | Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06948773) |
| March 26, 2025 | NCT06895486 | Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation | PATH | Phase 2 | Recruiting | Poliomyelitis | 675 | Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06895486) |
| March 19, 2025 | NCT06885034 | A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal... | GlaxoSmithKline | Phase 1/2 | Recruiting | Gastrointestinal Neoplasms | 346 | Australia, Belgium, Brazil, Canada, Finland, France, Germany, Italy, Japan... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06885034) |
| February 11, 2025 | NCT06819878 | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately... | Hoffmann-La Roche | Phase 3 | Recruiting | Moderately to Severely Active Crohns Disease | 600 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06819878) |
| January 28, 2025 | NCT06796907 | A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) | GlaxoSmithKline | Phase 1/2 | Recruiting | Tumours, Gynecological | 305 | Argentina, Australia, Belgium, Brazil, Canada, Denmark, Finland, France... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06796907) |
| January 13, 2025 | NCT06772142 | Early Feasibility of the Nervonik Peripheral Nerve Stimulation Device | Nervonik | Early phase 1 | Recruiting | Peripheral Nerve Disorder | 30 | Panama | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06772142) |
| November 13, 2024 | NCT06687369 | A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in... | mAbxience Research S.L. | Phase 3 | Active not recruiting | Non Squamous Non Small Cell Lung Cancer | 726 | Armenia, Bosnia and Herzegovina, Brazil, Georgia, Greece, Italy, Japan, Jordan... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06687369) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| GlaxoSmithKline | 4 | January 28, 2026 |
| Saint Thomas Hospital, Panama | 2 | December 4, 2025 |
| Sight Sciences, Inc. | 2 | May 27, 2025 |
| Edesa Biotech Inc. | 1 | October 22, 2026 |
| Endpoints Site Network | 1 | September 9, 2026 |
| ModernaTX, Inc. | 1 | September 9, 2026 |
| Vivifi Medical | 1 | August 4, 2026 |
| Fundación Judío Panameña (JUPA) | 1 | July 21, 2026 |
| Aquea Health, Inc. | 1 | July 13, 2026 |
| Francis Medical Inc. | 1 | May 1, 2026 |
| Nanochon, Inc. | 1 | April 21, 2026 |
| Perfect Lens, LLC | 1 | March 16, 2026 |
| Eduardo Lopez -Medina | 1 | November 25, 2025 |
| Lunair Medical | 1 | November 21, 2025 |
| Alcon Research | 1 | August 29, 2025 |
| Sanofi | 1 | August 5, 2025 |
| Hospital Civil de Guadalajara | 1 | July 11, 2025 |
| EyeD Pharma | 1 | June 25, 2025 |
| Drugs for Neglected Diseases | 1 | May 30, 2025 |
| ALPFA Medical | 1 | May 11, 2025 |

## Conditions

| Condition group | New trials | Latest |
| --- | --- | --- |
| Glaucoma, Open-Angle | 3 | July 13, 2026 |
| [Cataract](https://specstream.ai/data/clinical-trials/condition/cataract) | 3 | August 29, 2025 |
| Virus Diseases | 2 | September 9, 2026 |
| [Prostatic Hyperplasia](https://specstream.ai/data/clinical-trials/condition/prostatic-hyperplasia) | 2 | August 4, 2026 |
| [Pre-Eclampsia](https://specstream.ai/data/clinical-trials/condition/pre-eclampsia) | 2 | December 4, 2025 |
| Coronavirus Infections | 1 | September 9, 2026 |
| [COVID-19](https://specstream.ai/data/clinical-trials/condition/covid-19) | 1 | September 9, 2026 |
| [Prostatic Neoplasms](https://specstream.ai/data/clinical-trials/condition/prostatic-neoplasms) | 1 | May 1, 2026 |
| [Lupus Erythematosus, Systemic](https://specstream.ai/data/clinical-trials/condition/lupus-erythematosus-systemic) | 1 | January 28, 2026 |
| [Arthritis, Rheumatoid](https://specstream.ai/data/clinical-trials/condition/arthritis-rheumatoid) | 1 | January 28, 2026 |
| Myositis | 1 | January 28, 2026 |
| Sjogren's Syndrome | 1 | January 28, 2026 |
| [Endometrial Neoplasms](https://specstream.ai/data/clinical-trials/condition/endometrial-neoplasms) | 1 | December 16, 2025 |
| Pulmonary Edema | 1 | December 3, 2025 |
| Respiratory Tract Infections | 1 | November 25, 2025 |
| Sleep Apnea Syndromes | 1 | November 21, 2025 |
| Aphakia | 1 | August 29, 2025 |
| Yellow Fever | 1 | August 5, 2025 |
| [Glaucoma](https://specstream.ai/data/clinical-trials/condition/glaucoma) | 1 | June 25, 2025 |
| Ocular Hypertension | 1 | June 25, 2025 |
| Lens Diseases | 1 | June 25, 2025 |
| Poliomyelitis | 1 | March 26, 2025 |
| Gastrointestinal Neoplasms | 1 | March 19, 2025 |
| [Colorectal Neoplasms](https://specstream.ai/data/clinical-trials/condition/colorectal-neoplasms) | 1 | March 19, 2025 |
| [Neoplasms](https://specstream.ai/data/clinical-trials/condition/neoplasms) | 1 | January 28, 2025 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 13 | August 4, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 4 | October 22, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 4 | December 16, 2025 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 3 | June 25, 2025 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 2 | September 9, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 1 | January 28, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 1 | July 11, 2025 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 1 | January 13, 2025 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).